amsacrine has been researched along with Leukemia P388 in 41 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ER-37328 inhibited topoisomerase II activity at 10 times lower concentration than etoposide in relaxation assay and induced double-strand DNA cleavage within 1 h in murine leukemia P388 cells, in a bell-shaped manner with respect to drug concentration." | 3.71 | Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. ( Kamata, J; Kitoh, K; Kotake, Y; Koyanagi, N; Nagasu, T; Nakamura, K; Niijima, J; Okada, T; Sugumi, H; Uenaka, T; Yamaguchi, A; Yoshimatsu, K; Yoshino, H, 2002) |
| "Genistein is an inhibitor of the enzymes protein tyrosine kinase and topoisomerase-II." | 1.29 | Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. ( Baguley, BC; Finlay, GJ; Holdaway, KM, 1994) |
| " These data, together with reports indicating a protective effect of ruthenium red against vinblastine and anthracycline toxicity, suggest that the dye promotes tight binding of m-AMSA and other agents to cellular loci on which toxic effects are not exerted." | 1.27 | Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells. ( Kessel, D; Wilberding, C, 1984) |
| "P388/amsacrine, was however, as sensitive as cloned P388/S to camptothecin, an inhibitor of topoisomerase I." | 1.27 | Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. ( Crooke, ST; Drake, FH; Johnson, RK; Mattern, MR; Mirabelli, CK; Per, SR, 1987) |
| " Although intraperitoneal dosage was superior to intravenous or oral dosage for the treatment of intraperitoneally inoculated P388 leukaemia, all three routes of administration provided similar results with intravenously inoculated Lewis lung or subcutaneously implanted P388 cells." | 1.27 | Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma. ( Baguley, BC; Grimwade, CD; Kernohan, AR, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (60.98) | 18.7374 |
| 1990's | 14 (34.15) | 18.2507 |
| 2000's | 2 (4.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denny, WA | 11 |
| Rewcastle, GW | 6 |
| Baguley, BC | 20 |
| Yamato, M | 1 |
| Takeuchi, Y | 1 |
| Hashigaki, K | 1 |
| Ikeda, Y | 1 |
| Chang, MR | 1 |
| Takeuchi, K | 1 |
| Matsushima, M | 1 |
| Tsuruo, T | 1 |
| Tashiro, T | 1 |
| Tsukagoshi, S | 1 |
| Atwell, GJ | 8 |
| Finlay, GJ | 7 |
| Cain, BF | 1 |
| Wentland, MP | 2 |
| Lesher, GY | 1 |
| Reuman, M | 1 |
| Gruett, MD | 1 |
| Singh, B | 1 |
| Aldous, SC | 1 |
| Dorff, PH | 1 |
| Rake, JB | 2 |
| Coughlin, SA | 2 |
| Spicer, JA | 1 |
| Gamage, SA | 1 |
| Perni, RB | 1 |
| Huang, JI | 1 |
| Powles, RG | 1 |
| Aldous, S | 1 |
| Klingbeil, KM | 1 |
| Peverly, AD | 1 |
| Robinson, RG | 1 |
| Corbett, TH | 1 |
| Jones, JL | 1 |
| Mattes, KC | 1 |
| Bu, X | 1 |
| Deady, LW | 1 |
| Nakamura, K | 1 |
| Sugumi, H | 1 |
| Yamaguchi, A | 1 |
| Uenaka, T | 1 |
| Kotake, Y | 1 |
| Okada, T | 1 |
| Kamata, J | 1 |
| Niijima, J | 1 |
| Nagasu, T | 1 |
| Koyanagi, N | 1 |
| Yoshino, H | 1 |
| Kitoh, K | 1 |
| Yoshimatsu, K | 1 |
| Wilberding, C | 1 |
| Kessel, D | 2 |
| Twigden, SJ | 1 |
| Wilson, WR | 4 |
| Kernohan, AR | 2 |
| Wheeler, C | 1 |
| Chou, TH | 1 |
| Howard, WS | 2 |
| Johnson, RK | 6 |
| Holdaway, KM | 2 |
| Kimura, M | 1 |
| Kirshenbaum, MR | 1 |
| Chen, SF | 1 |
| Behrens, CH | 1 |
| Papp, LM | 1 |
| Stafford, MM | 1 |
| Sun, JH | 1 |
| Behrens, DL | 1 |
| Fredericks, JR | 1 |
| Polkus, ST | 1 |
| Sipple, P | 1 |
| Capranico, G | 2 |
| De Isabella, P | 1 |
| Tinelli, S | 1 |
| Bigioni, M | 1 |
| Zunino, F | 2 |
| Wodinsky, I | 1 |
| Swiniarski, J | 1 |
| Meaney, KF | 1 |
| Clement, JJ | 1 |
| Bailly, C | 1 |
| Collyn-d'Hooghe, M | 1 |
| Lantoine, D | 1 |
| Fournier, C | 1 |
| Hecquet, B | 1 |
| Fosse, P | 1 |
| Saucier, JM | 1 |
| Colson, P | 1 |
| Houssier, C | 1 |
| Hénichart, JP | 1 |
| Nakano, H | 1 |
| Waud, WR | 1 |
| Harrison, SD | 1 |
| Gilbert, KS | 1 |
| Laster, WR | 1 |
| Griswold, DP | 1 |
| Kohn, KW | 1 |
| Pommier, Y | 1 |
| Fray, LM | 1 |
| Palmer, BD | 1 |
| Lee, HH | 1 |
| Johnson, P | 1 |
| Wickham, G | 1 |
| Wakelin, LP | 1 |
| McFadyen, WD | 1 |
| Tan, KB | 1 |
| Mattern, MR | 3 |
| Eng, WK | 1 |
| McCabe, FL | 2 |
| Seneviratne, C | 1 |
| Goldenberg, GJ | 1 |
| Drake, FH | 2 |
| Zimmerman, JP | 1 |
| Bartus, HF | 1 |
| Per, SR | 2 |
| Sullivan, DM | 1 |
| Ross, WE | 1 |
| Crooke, ST | 2 |
| Schneider, E | 1 |
| Darkin, SJ | 1 |
| Lawson, PA | 1 |
| Ching, LM | 1 |
| Ralph, RK | 1 |
| Ganapathi, R | 1 |
| Grabowski, D | 1 |
| Schmidt, H | 1 |
| Seshadri, R | 1 |
| Israel, M | 1 |
| Mirabelli, CK | 1 |
| Gupta, SP | 1 |
| Ray, A | 1 |
| Handa, A | 1 |
| Prabhakar, YS | 1 |
| Aggarwal, D | 1 |
| Grimwade, CD | 1 |
1 review available for amsacrine and Leukemia P388
| Article | Year |
|---|---|
[Antitumor agents targeting mammalian topoisomerases].
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Diterpenes; DNA Topoisomerases, Type II; Doxorubici | 1991 |
40 other studies available for amsacrine and Leukemia P388
| Article | Year |
|---|---|
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Survival; Chemical Phenomena; Chemistry, Physic | 1990 |
Synthesis and antitumor activity of fused tetracyclic quinoline derivatives. 1.
Topics: Animals; Cell Line; Cell Survival; Chemical Phenomena; Chemistry; Colonic Neoplasms; DNA; DNA Topois | 1989 |
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Doxorubicin; Drug Resistance; Leukemia P388; L | 1987 |
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
Topics: Acridines; Aminoacridines; Amsacrine; Animals; Cell Line; Chemical Phenomena; Chemistry; Colonic Neo | 1986 |
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
Topics: Administration, Oral; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; DNA; Female; Inject | 1984 |
Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Indicators | 1983 |
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cattle; DNA; Drug Evaluation, Preclinical | 1983 |
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; DNA; Female; Leukemia L1210; Leukemia P38 | 1984 |
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
Topics: Aminoacridines; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; DNA; Leukemia L1210; | 1982 |
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; HeLa Cells; Humans; Leukemia P388; Mice; Quinolone | 1993 |
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Leuk | 1997 |
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enz | 1998 |
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
Topics: Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Doxorubicin; Drug Design; Drug Res | 2001 |
Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carbazoles; Colonic Neoplasms; Cross-Linking Reagents; DN | 2002 |
Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Division; Cell Line; Daunorubicin; L | 1984 |
Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cattle; Cell Division; Cell Line; Cell Su | 1984 |
Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Drug Admin | 1983 |
Studies on a mode of resistance to m-AMSA.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Doxorubicin; Drug Resistance; Leukemia P3 | 1982 |
Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Topics: Alkylating Agents; Aminacrine; Aminoacridines; Amsacrine; Animals; Antibiotics, Antineoplastic; Anti | 1982 |
Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Drug Resistance, Multiple; G2 | 1994 |
[Topoisomerase II mediated DNA strand cleavage and antitumor activities against murine leukemia P388 of novel acridines].
Topics: Acridines; Amsacrine; Animals; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, | 1994 |
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic | 1994 |
Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II.
Topics: Amsacrine; Animals; Base Sequence; Binding Sites; DNA; DNA Topoisomerases, Type II; DNA, Viral; Elec | 1993 |
Interaction of gamma-irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'- (acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Cell | 1979 |
Biological activity and molecular interaction of a netropsin-acridine hybrid ligand with chromatin and topoisomerase II.
Topics: Amsacrine; Animals; Body Weight; Cell Division; Chromatin; DNA Damage; Drug Design; Female; Fluorour | 1992 |
Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin | 1991 |
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Base Sequence; Daunorubicin; DNA, Viral; Doxorubici | 1990 |
Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Topics: Amsacrine; Animals; Antineoplastic Agents; DNA Topoisomerases, Type II; Drug Design; Drug Resistance | 1990 |
DNA-directed alkylating agents. 2. Synthesis and biological activity of platinum complexes linked to 9-anilinoacridine.
Topics: Alkylating Agents; Amsacrine; Animals; Chelating Agents; Chemical Phenomena; Chemistry; Cisplatin; D | 1990 |
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Topics: Alleles; Amsacrine; Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; | 1989 |
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
Topics: Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Colony-Forming Units Assay; I | 1989 |
Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia.
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Survival; Clone Cells; | 1989 |
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.
Topics: Amsacrine; Animals; DNA; DNA Topoisomerases, Type II; Drug Resistance; Immunosorbent Techniques; Iso | 1987 |
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Topics: Acridines; Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; DNA | 1988 |
Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Topics: Aminoacridines; Amsacrine; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agen | 1985 |
Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Topics: Amsacrine; Animals; Antineoplastic Agents; Clone Cells; DNA Damage; DNA Topoisomerases, Type II; Dru | 1987 |
Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.
Topics: Amsacrine; Animals; Cell Division; Cell Line; Doxorubicin; Drug Resistance; Leukemia P388; Leukemia, | 1988 |
Quantitative structure-activity relationship study on amsacrine derivatives.
Topics: Amsacrine; Animals; Cell Division; Chemical Phenomena; Chemistry, Physical; DNA; Leukemia P388; Mice | 1987 |
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Drug Evaluation, Preclinical; Female; Leukemia | 1987 |
Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Ad | 1985 |